These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38749882)

  • 1. Eflornithine for treatment of high-risk neuroblastoma.
    Jiang J; Yu Y
    Trends Pharmacol Sci; 2024 Jun; 45(6):577-578. PubMed ID: 38749882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eflornithine (Iwilfin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2024 May; 66(1702):e81-e82. PubMed ID: 38696315
    [No Abstract]   [Full Text] [Related]  

  • 3. Advancing neuroblastoma care: future horizons after approval of eflornithine by FDA.
    Nazir A; Nazir A; Kandel K
    Int J Surg; 2024 May; 110(5):2511-2512. PubMed ID: 38349215
    [No Abstract]   [Full Text] [Related]  

  • 4. DFMO inhibition of neuroblastoma tumorigenesis.
    Gandra D; Mulama DH; Foureau DM; McKinney KQ; Kim E; Smith K; Haw J; Nagulapally A; Saulnier Sholler GL
    Cancer Med; 2024 May; 13(9):e7207. PubMed ID: 38686627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.
    Schultz CR; Swanson MA; Dowling TC; Bachmann AS
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):607-617. PubMed ID: 34129075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval of DFMO for high-risk neuroblastoma patients demonstrates a step of success to target MYC pathway.
    Yang J
    Br J Cancer; 2024 Mar; 130(4):513-516. PubMed ID: 38316994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difluoromethylornithine in cancer: new advances.
    Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
    Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo-prevention.
    Smith KJ; Skelton H
    Int J Dermatol; 2006 Apr; 45(4):337-44. PubMed ID: 16650154
    [No Abstract]   [Full Text] [Related]  

  • 9. PACES trial: Evaluating the effectiveness of eflornithine and sulindac in preventing colon adenomas.
    Zell J; You YN; Boughey JC
    Bull Am Coll Surg; 2015 Aug; 100(8):70-1. PubMed ID: 26419059
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.
    Levin VA; Ictech SE; Hess KR
    CNS Oncol; 2018 Apr; 7(2):CNS16. PubMed ID: 29378419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.
    Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS
    Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
    Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
    Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Eflornithine in the treatment of African trypanosomiasis].
    Louis FJ; Keiser J; Simarro PP; Schmid C; Jannin J
    Med Trop (Mars); 2003; 63(6):559-63. PubMed ID: 15077414
    [No Abstract]   [Full Text] [Related]  

  • 14. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
    Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
    PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
    Makena MR; Cho HE; Nguyen TH; Koneru B; Verlekar DU; Hindle A; Kang MH; Reynolds CP
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27447. PubMed ID: 30251395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
    Von Hoff DD
    Clin Cancer Res; 1998 May; 4(5):1079-86. PubMed ID: 9607564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathways Involved in the Effect of Eflornithine in Neuroblastoma.
    Wolpaw AJ; Dang CV
    J Clin Oncol; 2024 Jan; 42(1):116-119. PubMed ID: 37883720
    [No Abstract]   [Full Text] [Related]  

  • 18. Eflornithine.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2244. PubMed ID: 11763800
    [No Abstract]   [Full Text] [Related]  

  • 19. Drugs recently released in Belgium. Eflornithine--finasteride.
    Harvengt C
    Acta Clin Belg; 1994; 49(1):42-6. PubMed ID: 7514829
    [No Abstract]   [Full Text] [Related]  

  • 20. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
    Lewis EC; Kraveka JM; Ferguson W; Eslin D; Brown VI; Bergendahl G; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Zage P; Rawwas J; Rich M; Lorenzi E; Broglio K; Berry D; Saulnier Sholler GL
    Int J Cancer; 2020 Dec; 147(11):3152-3159. PubMed ID: 32391579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.